Core Viewpoint - The company is actively working on the trial production of its 600,000-ton corn deep processing project, addressing bottlenecks and optimizing equipment and processes to ensure timely production launch [1]. Group 1: Project Development - The 600,000-ton corn deep processing and co-generation project is progressing smoothly in trial production [1]. - The project team is focused on overcoming identified bottlenecks during trial production [1]. - Continuous optimization of equipment and processes is being undertaken to expedite the project's launch [1]. Group 2: Company Positioning and Strategy - The company is a high-tech manufacturing enterprise centered on bio-fermentation and chemical synthesis, and it is the only listed platform under Guangxin Group for biomedicine and food health [1]. - The company aims to strengthen its management capabilities and align closely with its development strategy and operational goals [1]. - Efforts are being made to enhance core competitiveness and drive high-quality development to create greater value for shareholders [1].

Core Insights - Tangzhi Pharmaceutical has achieved a significant breakthrough in the preparation of carbohydrate raw materials, transitioning from milligram to kilogram scale production, with some products reaching over 98% purity, supporting downstream innovative drug development [3][4][5] - The market for nucleic acid raw materials is booming, with projections estimating it to reach a scale of hundreds of billions, driven by the rapid development of mRNA vaccines and the advantages of carbohydrate and nucleic acid drugs [4][5][6] - The company has established partnerships with over a hundred large pharmaceutical enterprises, with some products already in clinical trials, potentially leading to market approval by 2026 [3][4][6] Company Developments - Tangzhi Pharmaceutical has successfully industrialized key raw materials for mRNA drugs, including modified nucleotides and cap analogs, and is focusing on the synthesis and application of these materials [3][4] - The company has developed a biological platform that combines chemical synthesis and biological synthesis, significantly reducing production costs and increasing product purity [5][6] - The company is exploring the production of synthetic heparin, a widely used anticoagulant, through synthetic biology methods, aiming to overcome the limitations of traditional animal-derived sources [7][8] Market Trends - The rapid growth in the nucleic acid drug sector has led to increased demand for carbohydrate raw materials, prompting Tangzhi Pharmaceutical to ramp up production to ensure stable supply [6][8] - The application of AI in enzyme selection has improved research efficiency, allowing for faster identification of optimal candidates for synthesis processes [7] - The company has maintained a 50% annual revenue growth rate since its establishment in 2019, with expectations to surpass 100 million yuan in revenue by 2025 [8]